TD Cowen Cuts DarioHealth (NASDAQ:DRIO) Price Target to $8.00

DarioHealth (NASDAQ:DRIO) had its target price lowered by TD Cowen from $11.00 to $8.00 in a research report sent to investors on Wednesday morning,Benzinga reports. The brokerage currently has a hold rating on the stock.

Several other analysts also recently weighed in on DRIO. Weiss Ratings restated a “sell (e+)” rating on shares of DarioHealth in a research note on Friday, July 10th. Stifel Nicolaus reissued a “buy” rating and issued a $10.00 price objective on shares of DarioHealth in a research report on Thursday, May 14th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, DarioHealth has a consensus rating of “Hold” and a consensus price target of $9.00.

DarioHealth Stock Up 3.5%

DRIO opened at $7.59 on Wednesday. The firm has a market cap of $55.71 million, a P/E ratio of -1.24 and a beta of 1.11. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.62 and a current ratio of 2.31. The business has a 50 day moving average price of $7.10 and a 200 day moving average price of $8.23. DarioHealth has a twelve month low of $5.84 and a twelve month high of $17.74.

DarioHealth (NASDAQ:DRIO) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.22) by $0.37. The business had revenue of $5.18 million during the quarter, compared to the consensus estimate of $5.92 million. DarioHealth had a negative net margin of 169.87% and a negative return on equity of 54.81%. Research analysts forecast that DarioHealth will post -3.12 EPS for the current year.

Insider Buying and Selling

In other DarioHealth news, Director Dennis Matheis purchased 14,430 shares of the firm’s stock in a transaction on Thursday, July 23rd. The shares were purchased at an average price of $6.93 per share, for a total transaction of $99,999.90. Following the completion of the purchase, the director directly owned 43,026 shares of the company’s stock, valued at approximately $298,170.18. This represents a 50.46% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On DarioHealth

Hedge funds and other institutional investors have recently made changes to their positions in the business. XTX Topco Ltd grew its position in DarioHealth by 229.0% in the second quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock valued at $42,000 after acquiring an additional 43,513 shares during the period. Geode Capital Management LLC lifted its holdings in shares of DarioHealth by 167.9% during the fourth quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock valued at $564,000 after acquiring an additional 31,063 shares during the period. BlackRock Inc. acquired a new stake in shares of DarioHealth in the 2nd quarter valued at $249,000. Finally, Kestra Advisory Services LLC acquired a new stake in shares of DarioHealth in the 4th quarter valued at $35,000. 33.39% of the stock is owned by institutional investors.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.